Preferred Label : human papillomavirus vaccine, L1 type 16, 18;
MeSH note : vaccine containing L1 capsid proteins from types 16 and 18 of HPV (ALPHAPAPILLOMAVIRUS);
CISMeF synonym : GSK brand of HPV bivalent vaccine; cervarix;
MeSH synonym : HPV L1 vaccine, bivalent 16,18; human papillomavirus vaccine L1 16,18;
Is substance : O;
Origin ID : C510352;
UMLS CUI : C1721788;
ATC code(s)
- Automatic exact mappings (from CISMeF team)
- MeSH indexing information
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3161427/fr/cervarix
2020
false
false
false
France
human papillomavirus vaccine, L1 type 16, 18
vaccination
L1 protein, Human papillomavirus type 16
L1 protein, Human papillomavirus type 18
papillomavirus infections
precancerous conditions
anus neoplasms
uterine cervical neoplasms
papillomavirus (human types 16,18)
female
Male
evaluation of the transparency committee
papillomavirus vaccines
oncogene proteins, viral
capsid proteins
---
Summary Safety Review - Cervarix (Human Papillomavirus vaccine Types 16 and 18 [Recombinant,
AS04 adjuvanted]) - Assessing the Potential Risk of a Condition in which the body's
defense system damages nerves (Guillain-Barré Syndrome)
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/cervarix-fra.php
2016
false
false
false
Canada
French
English
drug evaluation
risk assessment
vaccination
guillain-barre syndrome
human papillomavirus vaccine, L1 type 16, 18
papillomavirus infections
uterine cervical neoplasms
anus neoplasms
product surveillance, postmarketing
papillomavirus (human types 16,18)
papillomavirus vaccines
---
http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=411
http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspa20140220_schemavaccinalHPVcervarix.pdf
2014
France
French
papillomavirus infections
papillomavirus vaccines
uterine cervical neoplasms
public health guidelines
adolescent
young adult
child
immunization schedule
human papillomavirus vaccine, L1 type 16, 18
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-08/cervarix_ct_5090.pdf
http://www.has-sante.fr/portail/jcms/c_657243/cervarix
http://www.has-sante.fr/portail/jcms/c_1232863/cervarix
http://www.has-sante.fr/portail/jcms/c_1233552/cervarix-01022012-avis-ct6893
2012
France
French
human papillomavirus vaccine, L1 type 16, 18
papillomavirus vaccines
vaccination
papillomavirus (human types 16,18)
insurance, health, reimbursement
vaccines, synthetic
adjuvants, immunologic
papillomavirus infections
uterine cervical neoplasms
L1 protein, Human papillomavirus type 16
L1 protein, Human papillomavirus type 18
treatment outcome
papillomavirus vaccines
human papillomavirus vaccine, L1 type 16, 18
oncogene proteins, viral
capsid proteins
oncogene proteins, viral
capsid proteins
clinical trials, phase ii as topic
clinical trials, phase iii as topic
randomized controlled trials as topic
papillomavirus vaccines
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_1250214/cervarix-vaccin-papillomavirus-humain-types-16-18-gardasil-vaccin-papillomavirus-humain-types-6-11-16-18
http://www.has-sante.fr/portail/jcms/c_1517921/fr/cervarix
2012
false
France
French
guidelines for drug use
evaluation of the transparency committee
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
immunization schedule
vaccination
papillomavirus vaccines
papillomavirus vaccines
uterine cervical neoplasms
papillomavirus infections
human papillomavirus vaccine, L1 type 16, 18
human papillomavirus vaccine, L1 type 16, 18
papillomavirus (human types 16,18)
treatment outcome
clinical trials, phase ii as topic
clinical trials, phase iii as topic
precancerous conditions
insurance, health, reimbursement
condylomata acuminata
---
https://www.ema.europa.eu/medicines/human/EPAR/Cervarix
2012
United Kingdom
English
French
syndication feed
Contraindications, Procedure
papillomavirus vaccines
pregnancy
breast feeding
drug interactions
papillomavirus vaccines
vaccination
papillomavirus infections
uterine cervical neoplasms
adolescent
adult
papillomavirus vaccines
papillomavirus vaccines
papillomavirus vaccines
treatment outcome
drug evaluation, preclinical
drug approval
drug labeling
human papillomavirus vaccine, L1 type 16, 18
papillomavirus (human types 16,18)
drug evaluation
summary of product characteristics
package leaflet
precancerous conditions
Contraindications, Drug
---
http://www.hcsp.fr/explore.cgi/hcspa20110121_ppmvjfCervarix.pdf
2011
France
French
papillomavirus vaccines
papillomavirus infections
human papillomavirus vaccine, L1 type 16, 18
Advertising
uterine cervical neoplasms
public health guidelines
---
https://www.inspq.qc.ca/sites/default/files/publications/795_avis_vaccins_papillomehumain.pdf
2008
false
Canada
French
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
uterine cervical neoplasms
papillomavirus vaccines
human papillomavirus vaccine, L1 type 16, 18
public health guidelines
---
http://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/13328488/Brochure%20HPV.pdf
2008
true
Belgium
French
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
papillomavirus infections
papillomavirus vaccines
papillomaviridae
belgium
sexual behavior
papillomavirus infections
papillomavirus infections
human papillomavirus vaccine, L1 type 16, 18
public health guidelines
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64098181
2008
France
French
human papillomavirus vaccine, L1 type 16, 18
L1 protein, Human papillomavirus type 18
L1 protein, Human papillomavirus type 16
suspensions
viral proteins
papillomavirus vaccines
papillomavirus (human types 16,18)
oncogene proteins, viral
oncogene proteins, viral
capsid proteins
capsid proteins
drug information
---
https://www.cadth.ca/sites/default/files/pdf/E0048_%20HPV-Vaccines_cetap_fr.pdf
https://www.cadth.ca/sites/default/files/pdf/E0048_%20HPV-Vaccines_cetap_e.pdf
2007
false
Canada
French
English
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
human papillomavirus vaccine, L1 type 16, 18
human papillomavirus vaccine, L1 type 16, 18
papillomavirus vaccines
uterine cervical neoplasms
vaccination
Cost-Benefit analysis
alphapapillomavirus
canada
papillomavirus infections
Evidence-Based medicine
papillomavirus vaccines
injections, intramuscular
uterine cervical neoplasms
papillomavirus vaccines
economic evaluation
drug evaluation
---
http://www.phac-aspc.gc.ca/naci-ccni/lr-sl_2-fra.php
http://www.phac-aspc.gc.ca//naci-ccni/lr-sl_2-eng.php
2007
false
Canada
English
French
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
papillomavirus infections
uterine cervical neoplasms
risk factors
papillomavirus vaccines
human papillomavirus vaccine, L1 type 16, 18
vaccination
review literature as topic
treatment outcome
papillomavirus vaccines
papillomavirus (human types 6,11,16,18)
drug information
---
